Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
Learn More
Invitrogen™ NLRC4 Monoclonal Antibody (GT1387)
Mouse Monoclonal Antibody
Supplier: Invitrogen™ MA527846
Description
Positive Control: human NLRC4-transfected 293T Predicted Reactivity: Bovine (82%) Store product as a concentrated solution. Centrifuge briefly prior to opening the vial.
NLRC4 encodes a member of the caspase recruitment domain-containing NLR family. Family members play essential roles in innate immune response to a wide range of pathogenic organisms, tissue damage and other cellular stresses. Mutations in this gene result in autoinflammation with infantile enterocolitis. Alternative splicing results in multiple transcript variants.
Specifications
NLRC4 | |
Monoclonal | |
1 mg/mL | |
PBS with no preservative | |
Q9NPP4 | |
Nlrc4 | |
Recombinant protein encompassing a sequence within the N-terminus region of human CARD12. The exact sequence is proprietary. | |
100 μL | |
Primary | |
Human | |
Antibody | |
IgG2a |
Western Blot, Immunocytochemistry | |
GT1387 | |
Unconjugated | |
Nlrc4 | |
9530011P19Rik; AIFEC; CARD, LRR, and NACHT-containing protein; Card12; caspase recruitment domain family, member 12; caspase recruitment domain-containing protein 12; CLAN; Clan protein; CLAN1; CLANA; CLANB; CLANC; CLAND; CLR2.1; FCAS4; ice protease-activating factor; ICE-protease activating factor; ipaf; NLR family CARD domain containing 4; NLR family CARD domain-containing protein 4; NLR family, CARD domain containing 4; NLRC4; NOD-like receptor C4; nucleotide-binding oligomerization domain, leucine rich repeat and CARD domain containing 4; UNQ6189/PRO20215 | |
Mouse | |
Protein A | |
RUO | |
58484 | |
Store at 4°C short term. For long term storage, store at -20°C, avoiding freeze/thaw cycles. | |
Liquid |
Product Content Correction
Your input is important to us. Please complete this form to provide feedback related to the content on this product.
Product Title
Spot an opportunity for improvement?Share a Content Correction